Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Liabilities and Shareholders Equity (2019 - 2023)

Historic Liabilities and Shareholders Equity for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $466.9 million.

  • ADC Therapeutics' Liabilities and Shareholders Equity fell 1219.71% to $466.9 million in Q3 2023 from the same period last year, while for Dec 2023 it was $1.4 billion, marking a year-over-year decrease of 3214.61%. This contributed to the annual value of $490.9 million for FY2022, which is 11.63% down from last year.
  • Latest data reveals that ADC Therapeutics reported Liabilities and Shareholders Equity of $466.9 million as of Q3 2023, which was down 1219.71% from $507.3 million recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Liabilities and Shareholders Equity registered a high of $638.0 million during Q3 2021, and its lowest value of $137682.0 during Q4 2019.
  • For the 5-year period, ADC Therapeutics' Liabilities and Shareholders Equity averaged around $401.7 million, with its median value being $479.3 million (2022).
  • As far as peak fluctuations go, ADC Therapeutics' Liabilities and Shareholders Equity soared by 12411985.76% in 2021, and later crashed by 1962.82% in 2023.
  • Quarter analysis of 5 years shows ADC Therapeutics' Liabilities and Shareholders Equity stood at $137682.0 in 2019, then surged by 278.79% to $521526.0 in 2020, then soared by 94129.37% to $491.4 million in 2021, then dropped by 0.12% to $490.9 million in 2022, then dropped by 4.88% to $466.9 million in 2023.
  • Its Liabilities and Shareholders Equity was $466.9 million in Q3 2023, compared to $507.3 million in Q2 2023 and $467.7 million in Q1 2023.